At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
LINX devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multicenter Study of REflux Management With the LINX® System for Gastroesophageal REFlux Disease After Laparoscopic Sleeve Gastrectomy
In Brief
A clinical study evaluating LINX device for GERD and Gastroesophageal Reflux Disease. Completed, enrolled 30 participants across 12 sites.
Detailed Summary
The purpose of this study is to evaluate the LINX device in patients who have previously undergone laparoscopic sleeve gastrectomy (LSG) for obesity and have chronic gastroesophageal reflux disease (GERD). The study will monitor safety and changes in reflux symptoms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGERD, Gastroesophageal Reflux Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartApr 2017
Primary CompletionJun 2021
TodayJul 2026
First PostedApr 29, 2015
Enrollment StartApr 5, 2017
Primary CompletionJun 8, 2021
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 11.2 years ago
Interventions
LINX devicedevice
The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.